Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PYGB | P11216 | 6/20 | 0.49 |
| ▸ | HK2 | P52789 | 5/20 | 0.47 |
| ▸ | HK1 | P19367 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12268046 | 1.00 | LMNA (0.55) | LMNAKDM4ECYP2D6CYP2C19PYGB | |
| SCHEMBL13483241 | 1.00 | LMNA (0.55) | LMNAKDM4ECYP2D6CYP2C19PYGB | |
| SCHEMBL17793804 | 1.00 | LMNA (0.55) | LMNAKDM4ECYP2D6CYP2C19PYGB | |
| SCHEMBL15928793 | 1.00 | LMNA (0.55) | LMNAKDM4ECYP2D6CYP2C19PYGB | |
| SCHEMBL20261723 | 1.00 | LMNA (0.55) | LMNAKDM4ECYP2D6CYP2C19PYGB | |
| SCHEMBL12336326 | 0.91 | LMNA (0.52) | LMNAKDM4ECYP2D6CYP2C19PYGB | |
| SCHEMBL15424839 | 0.88 | LMNA (0.55) | LMNAKDM4ECYP2D6CYP2C19PYGB | |
| SCHEMBL15966275 | 0.86 | PYGB (0.66) | LMNAKDM4ECYP2D6CYP2C19PYGB | |
| SCHEMBL22166026 | 0.86 | PYGB (0.66) | LMNAKDM4ECYP2D6CYP2C19PYGB | |
| SCHEMBL5158214 | 0.86 | PYGB (0.66) | LMNAKDM4ECYP2D6CYP2C19PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511118-A2 | GLYCOSYLATION INHIBITORS AS THERAPEUTICS FOR STROKE | The Regents of the University of California (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119300837-A | Glycosylation inhibitors as therapeutic agents for stroke | 加利福尼亚大学董事会 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023205124-A2 | GLYCOSYLATION INHIBITORS AS THERAPEUTICS FOR STROKE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-2338333-B1 | Glycopegylation methods and proteins/peptides produced by the methods | RATIOPHARM GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2322229-B1 | Remodeling and glycoconjugation of Factor IX | NOVO NORDISK AS (DK) | 2016-12-21 | — | — | EP | disclosed |
| EP-2042196-B1 | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) | RATIOPHARM GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-20160151400-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | UNIV JOHNS HOPKINS (US) | 2016-06-02 | — | — | US | disclosed |
| EP-2305314-B1 | Remodelling and glycoconjugation of antibodies | RATIOPHARM GMBH (DE) | 2015-12-23 | — | — | EP | disclosed |
| EP-2080525-B1 | Remodeling and glycoconjugation of poly(ether) to erythropietin | RATIOPHARM GMBH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | NOVO NORDISK AS (DK) | 2015-12-03 | — | — | US | disclosed |
| US-20040142856-A1 | Glycoconjugation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20040132640-A1 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20040126838-A1 | Follicle stimulating hormone: remodeling and glycoconjugation of FSH | NEOSE TECHNOLOGIES, INC. | 2004-07-01 | — | — | US | disclosed |
| US-20040115168-A1 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | NEOSE TECHNOLOGIES, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004033651-A2 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | NEOSE TECHNOLOGIES, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040043446-A1 | Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A | NEOSE TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003031464-A2 | REMODELING AND GLYCOCONJUGATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | CSF3R, CSF1R, GMFG | LMNA 4051/4885KDM4E 3276/4885CYP2D6 4875/4885 |
| US-20040142856-A1 | Glycoconjugation methods and proteins/peptides produced by the methods | PTMS, DNPEP, ANPEP | LMNA 2581/4885KDM4E 4241/4885CYP2D6 4817/4885 |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | IFNG, IFNAR1, IRF3 | LMNA 2247/4885KDM4E 4392/4885CYP2D6 4668/4885 |
| US-20160151400-A1 | HYBRID SCFA-HYDROXYL-DERIVATIZED MONOSACCHARIDES, METHODS OF SYNTHESIS, AND METHODS OF TREATING DISORDERS | HCAR2, HSD17B14, FASN | LMNA 1218/4885KDM4E 3383/4885CYP2D6 1075/4885 |
| US-20150343080-A1 | GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS | PTMS, ANPEP, NGLY1 | LMNA 1603/4885KDM4E 3684/4885CYP2D6 4857/4885 |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | PTMS, ANPEP, SMURF1 | LMNA 1066/4885KDM4E 3408/4885CYP2D6 4876/4885 |
| US-20040132640-A1 | Glycopegylation methods and proteins/peptides produced by the methods | PTMS, ANPEP, NGLY1 | LMNA 1603/4885KDM4E 3684/4885CYP2D6 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.